Numeric Investors LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,700 shares of the company’s stock, valued at approximately $274,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Victory Capital Management Inc. grew its holdings in IDEXX Laboratories by 11.8% in the first quarter. Victory Capital Management Inc. now owns 8,534 shares of the company’s stock worth $1,319,000 after purchasing an additional 901 shares during the last quarter. Wellington Management Group LLP purchased a new position in IDEXX Laboratories in the first quarter worth $15,851,000. FMR LLC grew its holdings in IDEXX Laboratories by 1,293.2% in the first quarter. FMR LLC now owns 36,419 shares of the company’s stock worth $5,630,000 after purchasing an additional 33,805 shares during the last quarter. Teachers Advisors LLC grew its holdings in IDEXX Laboratories by 38.4% in the first quarter. Teachers Advisors LLC now owns 184,963 shares of the company’s stock worth $28,597,000 after purchasing an additional 51,359 shares during the last quarter. Finally, Global X Management Co. LLC grew its holdings in IDEXX Laboratories by 44.6% in the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock worth $162,000 after purchasing an additional 323 shares during the last quarter. 87.58% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have issued reports on IDXX shares. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Friday, July 14th. Bank of America Corporation raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Finally, CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $174.00.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 17,000 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total transaction of $2,627,180.00. Following the transaction, the chairman now directly owns 1,039,034 shares of the company’s stock, valued at approximately $160,572,314.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $150.79, for a total transaction of $1,960,270.00. Following the transaction, the chairman now directly owns 1,044,034 shares in the company, valued at $157,429,886.86. The disclosure for this sale can be found here. Insiders have sold a total of 151,734 shares of company stock worth $23,436,626 over the last quarter. 2.77% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/numeric-investors-llc-invests-274000-in-idexx-laboratories-inc-idxx-stock/1638414.html.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 160.00 on Wednesday. The stock has a market capitalization of $13.96 billion, a price-to-earnings ratio of 55.04 and a beta of 0.48. The stock’s 50 day moving average is $156.99 and its 200-day moving average is $160.01. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The firm had revenue of $508.90 million for the quarter, compared to analyst estimates of $502.44 million. During the same period last year, the business earned $0.74 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.